1. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998;59:288-294.

2. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003;361: 1801-1809.

3. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2006:CD003429.

4. Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999;105:1109-1113.

5. Berntorp E. Prophylactic therapy for haemophilia: Early experience. Haemophilia 2003; 9(Suppl 1):5-9; discussion 9.

6. Blanchette VS, Manco-Johnson M, Santagostino E, et al. Optimizing factor prophylaxis for the haemophilia population: Where do we stand? Haemophilia 2004;10(Suppl 4):97-104.

7. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting factor Concentrate to Prevent Bleeding). MASAC Document #179. National Hemophilia Foundation 2007; 116 West 32nd Street, New York, NY 10001.

8. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-544.

9. Fiebig EW, Busch MP. Emerging infections in transfusion medicine. Clin Lab Med 2004;24:797-823.

10. Srivastava A. Optimizing clotting factor replacement therapy in hemophilia: A global need. Hematology 2005;10(Suppl 1):229-230.

11. MASAC Recommendations Concerning the Treatment of Hemophilia and Other Bleeding Disorders. MASAC Document #182. National Hemophilia Foundation 2008; 11ó West 32nd Street, New York, NY 10001.

12. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001;344:1773-1779.

13. Shord SS, Lindley CM. Coagulation products and their uses. Am J Health Syst Pharm 2000;57:1403-1417; quiz 1418-1420.

14. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987;ó9:454-459.

15. Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: A multiethnic study. J Pediatr 1993;123:893-898.

1ó. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (vWD): Evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008;14:171-232.

17. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004;351:ó83-ó94.

18. Friedman KD, Rodgers GM. Inherited coagulation disorders. In: Glader B, ed. Wintrobe's Clinical Hematology, Vol. 2. Philadelphia: Lippincott Williams and Wilkins, 2004:1ó19-1óó7.

19. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243-1252.

20. Roberts HR, Escobar MA. Other clotting factor deficiencies. In: Hoffman R, Benz EJJ, Shattil SJ, eds. Hematology: Basic Principles and Practice. Philadelphia: Elsevier, 2005:2047-20ó9.

21. Okajima K, Sakamoto Y, Uchiba M. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: A study of 204 cases. Am J Hematol 2000;ó5:215-222.

22. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007;35:2191-2195.

23. Rodgers GM. Acquired coagulation disorders. In: Greer JP, Foerster J, Lukens JN, et al., eds. Wintrobe's Clinical Hematology, Vol. 2. Philadelphia: Lippincott Williams and Wilkins, 2004:1óó9.

24. Levi M. Disseminated intravascular coagulation: What's new? Crit Care Clin 2005;21:449-467.

25. BickRL. Disseminated intravascular coagulation: Pathophysiological mechanisms and manifestations. Semin Thromb Hemost 1998;24:3-18.

26. de Pont AC, Bakhtiari K, Hutten BA, et al. Recombinant human activated protein C resets thrombin generation in patients with severe sepsis—A case control study. Crit Care 2005;9:R490-R497.

27. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. Highdose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001;286:1869-1878.

28. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909-913.

29. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.

30. Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: Immediate response to therapy and long-term outcome. J Pe-diatr 1998;133:334-339.

31. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.

32. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584.

33. Sadler J, Poncz M. Antibody-mediated thrombotic disorders: Idiopathic thrombotic thrombocytopenic purpura and heparin-induced thrombocytopenia. In: Licht-man M, ed. Williams Hematology. New York: McGraw-Hill, 2006:2031-2054.

68 Sickle Cell Anemia

Tracy M. Hagemann and Teresa V. Lewis


Natural Arthritis Relief

Natural Arthritis Relief

Natural Arthritis Relief details a unique method of reversing Rheumatoid Arthritis Symptoms by removing numerous arthritis triggers as well as toxins using a simple 5 step natural process.

Get My Free Ebook

Post a comment